Hereditary cancer test finds 105 percent more mutations Myriad Genetics, Inc. (NASDAQ: MYGN) today announced results from a new study that demonstrated the ability of the myRisk™ Hereditary Cancer test to detect 105 percent more mutations in cancer causing genes than conventional BRCA testing a…
Source:Myriad Genetics highlights three new studies at SABCS 2014
Wednesday, December 10, 2014
Myriad Genetics highlights three new studies at SABCS 2014
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment